The 1.5 billion yuan drug market is fiercely competitive, and a large number of pharmaceutical companies have been evaluated recently

【Pharmaceutical Network Market Analysis】On October 25, the NMPA released a new batch of drug approval documents to be received, among which, a number of varieties of cefixime drugs were again evaluated by enterprises, involving Lijian Pharmaceutical, Shanghai Haihong Pharmaceutical and Sichuan Saizhuo Pharmaceutical
.
According to public information, cefixime is the first third-generation oral cephalosporin, which is clinically suitable for bacterial infectious diseases
caused by Streptococcus and influenza bacillus sensitive to cefixime.
The original manufacturer of the drug is Fujisawa Pharmaceutical Industry Co.
, Ltd.
, Japan, and has been widely used in clinical use
in more than 80 countries since its launch in 1987.
At present, various dosage forms
of tablets, capsules, granules and oral liquids have been developed.
In China, the currently approved cefixime dosage forms include ordinary tablets, dispersible tablets, chewable tablets, dry suspension and granules
.
Among them, capsules and tablets are the main sales dosage forms
.
According to statistics, the sales of cefixime drugs in the hospital in 2021 will be 1.
59 billion yuan, of which cefixime dispersible tablets have a high market share, followed by cefixime capsules and cefixime granules
.
From the perspective of enterprises, Baiyunshan Pharmaceutical General Factory accounts for a relatively large proportion, and its 2020 annual report disclosed that the sales of cefixime series drugs were 925 million yuan
.
At present, there are many cefixime drug market layouts, in addition to the above companies, this year there are also many pharmaceutical companies have cefixime products on the market, have been evaluated
.
For example, in early October, the website of the State Food and Drug Administration showed that Jiangsu Zhengda Qingjiang Pharmaceutical's cefixime tablets were approved for supplementary application, becoming the fourth enterprise to pass the evaluation of the product, and then the company's ellamod tablets were accepted
by CDE for imitation of Class 4 applications.
On July 8, Zhongsheng Pharmaceutical issued an announcement that cefixime dispersible tablets passed the consistency evaluation
.
Zhongsheng Pharmaceutical said that the evaluation of cefixime dispersible tablets will be conducive to the future market sales of the product, build a favorable market competitive position, and have a positive impact
on the company.
On March 9, Fangsheng Pharmaceutical issued an announcement that cefixime tablets received the "Drug Supplement Application Approval Notice" issued by the State Food and Drug Administration, and passed the consistency evaluation
of the quality and efficacy of generic drugs 。 .
.
.
.
.
.
On the whole, there are many market layouts of the drug, according to incomplete statistics, there are currently 19 domestic cefixime tablets with production approvals; 25 manufacturers of cefixime capsules have been approved for production, and a total of 10 have passed the consistency evaluation; Cefixime dispersible tablets have 12 companies listed, and 4 manufacturers have passed the consistency evaluation before.
.
.
On the whole, a total of 38 specifications have passed the consistency evaluation in the cefixime market, of which 13 specifications have been included in the 7th batch of centralized procurement
.
The industry believes that the competition in the domestic cefixime market has been very fierce, and the competition in this field is expected to continue to intensify
as companies continue to increase their code in the future.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice
to anyone.